Equillium, Inc.
EQ · XNASCIK 1746466fmd_1QAJTQ9NP053YPH8RG0D37DHXAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 38 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 16 | 36 | 41 | – |
| Research and development | 5 | 18 | 19 | 26 | 38 | 37 | 37 | 13 |
| Total operating expenses | 9 | 27 | 30 | 38 | 78 | 51 | 49 | 24 |
| Operating income | (9) | (27) | (30) | (38) | (62) | (15) | (8) | (24) |
| Interest expense | 3 | 0 | 1 | 1 | 1 | 0 | – | – |
| Interest and investment income | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 1 |
| Other non-operating income (expense) | (5) | 1 | (0) | (1) | (0) | 2 | – | – |
| Income before taxes | (13) | (26) | (30) | (39) | (62) | (13) | (8) | (22) |
| Income tax expense | – | – | 0 | 0 | 0 | 1 | 0 | 0 |
| Net income from continuing operations | – | – | (30) | (39) | (62) | (13) | (8) | (22) |
| Net income | (13) | (26) | (30) | (39) | (62) | (13) | (8) | (22) |